Arrowhead Research: Fiscal Q1 Earnings Snapshot
Arrowhead Research: Fiscal Q1 Earnings Snapshot
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz Strong
Piper reduced Sarepta’s price target to $182 from $200, highlighting the partnership’s near-term financial impact.
Arrowhead Pharma Stock Soars Pre-Market On $825M Sarepta Licensing Deal: Retail Activity Hits Year-High
The global licensing deal includes $500 million in cash and $325 million in equity, at a 35% premium upon closing.
Arrowhead Research: Fiscal Q3 Earnings Snapshot
Arrowhead Research: Fiscal Q3 Earnings Snapshot
Arrowhead Research: Fiscal Q2 Earnings Snapshot
Arrowhead Research: Fiscal Q2 Earnings Snapshot
Arrowhead Research: Fiscal Q1 Earnings Snapshot
Arrowhead Research: Fiscal Q1 Earnings Snapshot
Arrowhead Research: Fiscal Q3 Earnings Snapshot
Arrowhead Research: Fiscal Q3 Earnings Snapshot
Arrowhead Research: Fiscal Q2 Earnings Snapshot
Arrowhead Research: Fiscal Q2 Earnings Snapshot
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023. The company is hosting a conference call today, May 2, 2023, at 4:30...